CCK<sub>2</sub>Receptor Ligand [<sup>68</sup>Ga]Ga-DOTA-CCK-66 PET/CT Outperforms [<sup>68</sup>Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer
Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers and is characterized by an exceptionally high proliferative rate, a strong tendency for early metastasis, and a poor prognosis ([1][1]). Cholecystokinin-2 receptor (CCK2R) is overexpressed in more than half of SCLC
Authors
- Veronika Felber (ORCID: https://orcid.org/0000-0003-0072-9769)
- Niklas Dreher (ORCID: https://orcid.org/0000-0003-2921-8452)
- Thomas Günther
- Adriana Amerein
- Rainer Claus (ORCID: https://orcid.org/0000-0003-2617-8766)
- Malte Kircher (ORCID: https://orcid.org/0000-0003-4355-0881)
- Oliver Viering
- Johanna S. Enke (ORCID: https://orcid.org/0000-0002-2690-8856)
- Nadine Holzleitner (ORCID: https://orcid.org/0000-0001-8258-3526)
- Constantin Lapa (ORCID: https://orcid.org/0000-0001-7536-2207)
- Christian H. Pfob (ORCID: https://orcid.org/0000-0003-2989-5883)
- Alexander Dierks
Institutions
- Technische Hochschule Augsburg (DE)
- University of Augsburg (DE)
- Stanford Medicine (US)
- Technical University of Munich (DE)
- Stanford University (US)
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2025-02-20
- DOI
- https://doi.org/10.2967/jnumed.124.269201
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05